Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
  • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
  • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
  • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
  • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
  • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07J—STEROIDS
  • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Definitions

• the present invention relates to Fulvestrant prodrugs and process for the preparation thereof.
• the present disclosure also relates to pharmaceutical composition of Fulvestrant prodrugs and method of treatment using the same.
• Fulvestrant is an estrogen receptor antagonist marketed as FaslodexTM for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. Fulvestrant has clinical therapeutic effect in patients failed in treatment with tamoxifen. Therefore, among many drugs for treating breast cancer, Fulvestrant is the only anti-estrogen agent that may be widely used in clinical treatment after the failure of tamoxifen, which has initiated a new way of treating hormone- sensitive breast cancer. Due to the poor solubility and oral bioavailability of Fulvestrant, the drug is currently administered via intramuscular injection of an oil-based Fulvestrant formulation. The FaslodexTM product is approved for administration by intramuscular injection on days 1, 15, 29 and once monthly thereafter.
• This injection contains upto 10% of benzyl alcohol which might act as anaesthetic level while castor oil is used as release rate modifier which can be painful at the time of injection due to high viscosity. According to FDA drug approval summaries, injection site reaction and hot flashes were observed.
• Fulvestrant is a highly lipophilic molecule which is practically insoluble in water. This restricts their bioavailability. A drug with poor solubility will often exhibit poor bioavailability and require administration of high dosages to attain therapeutically effective blood levels of the drug.
• prodrugs allows the artisan to modify one or more properties of a biologically active compound.
• Prodrugs include chemical derivatives of a biologically active parent compound which, upon administration, will eventually liberate the active parent compound in vivo.
• the rate of release of the active drug is influenced by several factors including the rate of hydrolysis of the linker which joins the parent biologically active compound to the prodrug carrier.
• W02016/004166 A1 discloses boron based Fulvestrant prodrugs for the treatment of breast cancer.
• the application also discloses the need of improved bioavailability of Fulvestrant to make it more effective therapeutic regimen for tamoxifen-resistant breast cancer.
• the utility of Fulvestrant has been limited by the amount of drug that can be administered in a single injection and by reduced bioavailability.
• an object of the present invention is to provide a compound or a salt thereof that can overcome the above challenges and is metabolized rapidly to produce Fulvestrant in the body.
• the present invention relates to compound of formula I: wherein; Ri is wherein R17 is selected from NH2 , NHR18 , or NR 19 R 20 ; R18 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, halo
• R 2 is selected independently from group comprising of: i) wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl
• the present invention relates to compound of formula IV : wherein R 7 is ; wherein each R 25 and R 26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and R8 is selected independently from group comprising of: i) wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl
• the present invention relates to compound of formula VI: wherein, Rio is wherein R 28 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein one or more substitution is selected from formyl, halo, phosphate, cyano, nitro, amino, hydroxy, heterocycloalkyl, or alkoxy; and Rii is hydrogen or where R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted
• the present invention relates to compound of formula VIII: wherein R 13 is selected from hydrogen, alkyl; and
• R 14 is selected from group comprising optionally substituted alkyl, heterocycloalkyl, or aryl; wherein one or more substitution is selected from alkyl, alkoxy, halo, heteroaryl, heterocycloalkyl, cycloalkyl, amino, or hydroxy; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to prodrugs of Fulvestrant of formula IX: wherein S is selected from O, C, or N; and
• T is selected from group comprising optionally substituted aryl, heteroaryl, heterocycloalkyl, cycloalkyl, amino, ; wherein one or more substitution is selected from alkyl, alkoxy; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to prodmgs of Fulvestrant of formula X: wherein, Q is selected from C or N; and when Q is C, Pi is selected independently from optionally substituted alkyl, optionally substituted ; wherein substitution on is alkyl; and P 2 and P 3 is selected independently from hydrogen or alkyl; and when Q is N, P 2 is selected independently from optionally substituted alkyl, optionally substituted ; wherein substitution on is alkyl; Pi is hydrogen and P 3 is optionally substituted alkyl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula XI: wherein R 15 and Ri 6 together forms a cyclic structure; wherein the said cyclic structure is selected from optionally substituted cycloalkyl, or heterocycloalkyl; wherein one or more substitution is selected from alkyl, alkoxy, halo, amino, or hydroxy; m and n can be independently 1 to 3; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula XI where m and n both are 1 or 2.
• the present invention relates to pharmaceutical composition
• pharmaceutical composition comprising Fulvestrant prodrug and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof and pharmaceutically acceptable excipients.
• the pharmaceutical compositions of the present disclosure can be in any form known to those of skill in the art.
• the pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally or via an implanted reservoir, preferably oral administration or administration by injection.
• the invention provides use of compounds of the present invention in the preparation of a pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.
• the invention provides compounds for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.
• prodrug refers to a precursor compound that, following administration, releases a biologically active compound in vivo via a chemical or physiological process.
• a prodrug itself may either lack or possess the desired biological activity.
• cancer refers to conditions including solid cancers, lymphomas and leukemias.
• types of cancer include, but are not limited to, breast cancer, lung cancer, ovarian cancer, prostate cancer, colorectal cancer, liver cancer, renal cancer, bladder cancer, thyroid cancer, pleural cancer, pancreatic cancer, uterine cancer, cervical cancer, testicular cancer, anal cancer, bile duct cancer, gastrointestinal carcinoid tumors, esophageal cancer, gall bladder cancer, appendix cancer, small intestine cancer, stomach cancer, cancer of the central nervous system, skin cancer, choriocarcinoma, head and neck cancer, blood cancer, osteogenic sarcoma, fibrosarcoma, neuroblastoma, glioma, melanoma, B-cell lymphoma, non-Hodgkin's lymphoma, Burkitfs lymphoma, small cell lymphoma, large cell lymphoma, monocytic leukemia, myelogen
• alkyl refers to a straight or branched, saturated, aliphatic radical having from 1 to about 10 carbon atoms., for example, methyl, ethyl, propyl, isopropyl, n-butyl, i- butyl, t-butyl and the like.
• alkynyl denotes an alkynyl groups having from 2 to 10 carbon atoms and having at least 1-2 sites of alkynyl unsaturation, preferred alkynyl groups include ethynyl (- CoCH), propargyl (-CH2-CoCH), 1-butenyl, 2-butenyl, isobutenyl, butadienyl and the like.
• cycloalkyl denotes a saturated carbocyclic group having from 3 to 10 carbon atoms having a single ring (e.g., cyclohexyl) or multiple condensed rings (e.g., norbornyl).
• Preferred cycloalkyl include cyclopropyl, cyclobutyl, cyclpentyl, cyclohexyl, cycloheptyl, norbornyl and the like.
• heterocyclic ring denotes organic compounds that contain a ring structure containing atoms in addition to carbon, such as sulphur, oxygen or nitrogen, as part of the ring. There can be more than one hetero atom substitution in the ring structure selected from sulphur, oxygen or nitrogen.
• the ring can be saturated, partially saturated or unsaturated ring structure which includes “heterocycloalkyl” and “heteroaryl”.
• heterocycloalkyl denotes a C3-C10 cycloalkyl group according to the definition above, in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N.
• Preferred heterocycloalkyl include pyrrolidine, piperidine, piperazine, morpholine, tetrahydrofuran, tetrahydrothiophenyl, and the like.
• aryl denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 6-14 carbon atoms in which at least one ring is aromatic in nature, for example phenyl, naphthyl, 1,2,3,4-tetrahydronaphthalenyl, indanyl and the like.
• heteroaryl denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 5-14 ring atoms, preferably containing 5-10 ring atoms, in which at least one ring is aromatic in nature, and which contains at least one heteroatom, selected from N, O or S, for example pyridyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, imidazo[l,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, benzoquinoly
• halogen denotes chlorine, iodine, fluorine and bromine.
• leaving group or “L” or “Li” can be defined as part of a substrate that cleaved by the action of a nucleophile.
• leaving groups include, but are not limited to: halogen (F, Cl, Br, and I), tosylate, mesylate, triflate, acetate, hydroxyl, camphorsulfonate, aryloxide, and aryloxide and the like.
• alkoxy refers to the group -O-alkyl.
• alkoxyalkyloxy refers to the group alkyl-O-alky-O-
• alkoxycarbonyloxy refers to the group alkyl-O-CO-O-.
• phosphate refers to -0-PO(OH) 2 .
• phosphonyl refers to -PO 3 H 2 .
• alkylphosphate refers to (-alkyl-O- PO(OH) 2 ).
• amino acid refers to two stereoisomeric forms, called “D” and “L.”
• the D and L form of any amino acid have identical physical properties and chemical reactivities, but rotate the plane of plane-polarized light equally but in opposite directions and react at different rates with asymmetric reagents. All naturally occurring amino acids in proteins are in the L form.
• Amino acid comprises lysine, valine, tryptophan, phenylalanine, methionine, leucine, threonine, isoleucine, arginine, histidine, tyrosine, carnitine, serine, glutamine, aspartic acid, proline, glycine, cysteine, alanine, glutamic acid.
• Amino acid may be present as either “D” or “L” enantiomer.
• -C(0)-aminoacid referes to the amino acid attached to carbonyl group via amide or ester linkage: more preferably via amide linkage.
• pharmaceutically acceptable carrier refers to a non-toxic carrier that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
• pharmaceutically acceptable excipient includes vehicles, adjuvants, or diluents or other auxiliary substances, such as those conventional in the art, which are readily available to the public.
• pharmaceutically acceptable excipients include pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like.
• salts of basic compounds are salts formed with mineral acids, organic carboxylic acids, organic sulfonic acids, and the like.
• suitable acids include hydrochloric, hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene- 2- sulfonic and benzenesulfonic acids.
• Salts of acidic compounds are formed with bases, namely cationic species such as alkali and alkaline earth metal cations e.g., sodium, lithium, potassium, calcium, and magnesium ions as well as ammonium cations e.g., ammonium, trimethylammonium and diethylammonium.
• Salts of acidic compounds are formed with organic bases, namely tromethamine and meglumine.
• the compounds of this invention contain one or more asymmetric carbon atoms and thus occur as racemate and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
• Each stereogenic carbon may be of the R or S configuration.
• deprotecting agents includes, but are not limited to, hydrogen and palladium on carbon (3 ⁇ 4, Pd/C), ammonium formate and palladium on carbon (HCOONH4, Pd/C), hydrogen and palladium hydroxide on carbon (3 ⁇ 4, Pd(OH)2/C), combination of Pd/C and Pd(OH)2/C and acid such as hydrochloride acid, hydrobromic acid and the like.
• substituted shall be understood to include adding or replacing one or more atoms contained within a functional group or compound with one or more different atoms.
• substituents selected from the group consisting of “Cl-C8-alkyl”, “C2-C8-alkenyl”, “C2-C8-alkynyl”, “cycloalkyl”, “heterocycloalkyl”, “aryl”, “heteroaryl”, “amino”, “alkylamino”, “acyl”, “acyloxy”, “acylamino”, “aminocarbonyl”, “alkoxycarbonyl”, “alkoxyalkyloxy”, “alkoxycarbonyloxy”, “carbamate,” “sulfmyl”, “sulfonyl”, “alkoxy”, “sulfanyl”, “halogen”, “carboxy”, “trihalomethyl”, “cyano”, “hydroxy”, “mercapto”, “nitro”, “phosphate”, “alkylphosphate” and the like.
• the preferred one or more substituents is selected from 1 to 10 in number; more preferably from 1 to 5 in number.
• Coupled reagent includes but not limited to 0-benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-phosphate (HBTU), 2-(7 -Aza-IH- benzo triazole- 1-yl)- 1,1, 3, 3 -tetramethyluroniumhexafluorophosphate (HATU), acid halide, 1- hydroxybenzotriazole (HOBt), l-Hydroxy-7-aza-lH-benzotriazole (HOAt), diisopropylcarbodiimide (DIC), dicyclohexylcarbodiimide (DCC), N-(3-Dimethylaminopropyl)- A'-cthylcarbodiimidc hydrochloride (EDC), 2-(6-Chloro-lH-benzotriazol-l-yl)-N,N,N’,N’- tetramethylamin
• Base used in the present invention can be inorganic and organic base.
• organic base includes but not limiting to amines such as diisopropylethylamine, triethylamine, pyridine, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), imidazole, N,N-dimethyl aniline, N,N- dimethyl amino pyridine (DMAP), l,5-diazabicyclo[4.3.0]non-5-ene (DBN) and the like or mixtures thereof.
• amines such as diisopropylethylamine, triethylamine, pyridine, l,8-diazabicyclo[5.4.0]undec-7-ene (DBU), imidazole, N,N-dimethyl aniline, N,N- dimethyl amino pyridine (DMAP), l,5-diazabicyclo[4.3.0]non-5-ene (DBN) and the like
• inorganic base includes but not limiting to alkali or alkaline earth metal carbonate, bicarbonate, hydroxide or phosphate such as potassium carbonate, sodium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium phosphate, sodium phosphate; hydride such as sodium hydride, lithium hydride or potassium hydride; alkoxide such as sodium or potassium methoxide or ethoxide, tertiary butoxide and the like or mixtures thereof.
• alkali or alkaline earth metal carbonate, bicarbonate, hydroxide or phosphate such as potassium carbonate, sodium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, lithium bicarbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, potassium phosphate, sodium phosphate
• hydride such as sodium hydride, lithium hydride or potassium hydride
• alkoxide such as sodium or potassium me
• solvent refers to the solvents include, but are not limited to, nitriles such as acetonitrile, propionitrile, butyronitrile, isobutyronitrile and the like; ethers such as dioxane, diethyl ether, diisopropylether, tetrahydrofuran, dimethoxyethane and the like; hydrocarbon such as toluene, xylene, hexane, heptane, cyclohexane and the like; chlorinated hydrocarbon such as methylene chloride, ethylene dichloride, carbon tetra chloride, chloroform, chlorobenzene and the like; polar aprotic solvents such as N,N-dimethylformamide (DMF), dimethyl acetamide (DMAc), dimethyl sulfoxide (DMSO) and the like or mixtures thereof.
• nitriles such as acetonitrile, propionitrile, butyronitrile
• novel compounds of the present invention can be used in conventional solid or liquid pharmaceutical forms, for example as uncoated or film coated tablets, capsules, powders, granules, solutions or sprays.
• the active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, bulking agents, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, release-slowing agents, antioxidants and/or propellant gases.
• the prodrugs of the present invention are characterized by unexpectedly high aqueous solubility. This solubility facilitates administration of higher doses of the prodrug, resulting in a greater drug load per unit dosage.
• the prodrugs of the present invention are also characterized by facile hydrolytic cleavage to release the active Fulvestrant in vivo. The high aqueous solubility and the facile in vivo metabolism result in a greater bioavailability of the drug.
• compositions according to this invention may be comprised of a combination of a prodrug of this invention and another therapeutic agent.
• the present invention relates to compound of formula I: wherein; Ri is wherein Rn is selected from NFh, NHRis , or NR 19 R 20 ; Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, al
• R 2 is selected independently from group comprising of: i) wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl
• the present invention relates to compound of formula I: wherein; Ri is wherein Rn is selected from NH 2 , NHRis , or NR 19 R 20 ; Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl,
• R 2 is wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl
• the present invention relates to compound of formula I: wherein; Ri is wherein R17 is selected from NH 2 , NHRis , or NR 19 R 20 ; Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl,
• R 2 is wherein each R 25 is selected independently from hydrogen; optionally substituted alkyl, aryl, or heteroaryl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula I: wherein; Ri is wherein R17 is selected from NH 2 , NHRis , or NR 19 R 20 ; Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl,
• R 2 is wherein each R 26 is selected independently from hydrogen; optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula I: wherein; Ri is wherein Rn is selected from Nth, NHRis , or NR 19 R 20 ; Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alky
• the present invention relates to compound of formula II: wherein X is selected from O, C, N; and
• Y is selected from optionally substituted aryl, heteroaryl, heterocycloalkyl, or cycloalkyl; and R 3 is selected independently from group comprising of: i) wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23 ; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl
• the present invention relates to compound of formula II: wherein X is selected from O, C, N; and Y is selected from group comprising optionally substituted aryl, heteroaryl, heterocycloalkyl, or cycloalkyl; wherein the one or more substitution is selected from alkyl or alkoxy; and R 3 is selected independently from group comprising of: i) wherein R 21 is optionally substituted alkyl; wherein one or more substitution is selected from amino, phosphate, alkylphosphate, or hydroxy; ii) wherein each R 25 is selected independently from group comprising of hydrogen; optionally substituted alkyl; iii) wherein each R 26 is selected independently from hydrogen; optionally substituted alkyl; iv) amino acids; wherein the amino acid is linked via ester linkage at the point of attachment; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula III: wherein; R 5 is selected from hydrogen, alkyl;
• R 6 is selected from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, or cycloalkyl;
• R 4 is selected independently from group comprising of: i) wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, hydroxy, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxy
• the present invention relates compound of formula III:
• R 5 is selected from hydrogen, alkyl
• R6 is selected from group comprising optionally substituted alkyl or aryl, wherein one or more substitution is selected from alkyl, alkoxy, halo, heteroaryl, heterocycloalkyl, cycloalkyl, amino, or hydroxy; and
• R 4 is selected independently from group consisting of: i) wherein R 21 is optionally substituted alkyl; wherein one or more substitution is selected from amino, phosphate, alkylphosphate, or hydroxy; ii) wherein each R 25 is selected independently from hydrogen, or optionally substituted alkyl; iii) wherein each R 26 is selected independently from hydrogen or optionally substituted alkyl; iv) amino acids, wherein the amino acid is linked via ester linkage at the point of attachment; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound selected from group consisting of: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula IV : wherein R 7 is wherein each R 25 and R 26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and Rs is selected independently from group comprising of:
• R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkyny
• R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkynyl,
• the present invention relates to compound of formula IV : wherein R 7 is 0 , or ° ; wherein each R 25 and R 26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and Rl7
• Rn is selected from Nth, NHRis or NR 19 R 20 ;
• Ris is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• R 19 and R 20 are selected independently from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 19 and R 20 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, oxo, cyano, nitro
• the present invention relates to compound of formula IV : wherein R 7 is O , or O ; wherein each R 25 and R 26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and
• R 27 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula IV : wherein R7 is ; wherein each R25 and R26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and
• R28 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl; wherein one or more substitution is selected from formyl, halo, phosphate, cyano, nitro, or amino; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula IV : wherein R7 is ; wherein each R25 and R26 is selected independently from hydrogen; optionally substituted alkyl, aryl or heteroaryl; and
• Rs is amino acid, wherein the amino acid is linked via ester linkage at the point of attachment; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula V : wherein W is selected from group comprising of hydrogen, or optionally substituted alkyl; and R9 is selected independently from group comprising of: i) wherein R21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR22R23; where R22and R23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, aryl, heteroaryl; ii) O wherein Rn is selected from NHR
• the present invention relates to compound of formula V-A: wherein W is selected from group comprising of hydrogen, or optionally substituted alkyl; and R 9 is selected independently from group comprising of:
• R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23 ; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, aryl, heteroaryl; ii) O wherein Rn is selected from NHRis, or NR 19 R 20; wherein Ris is selected from group comprising optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl and hetero
• the present invention relates to compound selected from group consisting of: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound selected from group consisting of: pharmaceutically acceptable salts or solvates thereof. In another embodiment, the present invention relates to compound: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula VI: wherein, Rio wherein R28 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein one or more substitution is selected from formyl, halo, phosphate, cyano, nitro, amino, hydroxy, heterocycloalkyl, or alkoxy; and 3 ⁇ 41
• Rii is hydrogen or O where R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, amino, alkoxycarbonyl, alkenyl, alkyn
• the present invention relates to compound of formula VII: wherein, each Zi and Z 2 is independently selected from optionally substituted hydroxy, phosphate, or heterocycloalkyl; and
• R 12 is hydrogen or O wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl; or -CR 22 R 23 ; where R 22 and R 23 are taken together along with the carbon to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring in which up to 4 carbon atoms are replaced by heteroatoms chosen from the group consisting of O, S or N and may optionally be substituted at a substitutable position with one or more R 24 radicals, wherein one or more R 24 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkylcarbonyl, formyl, halo, alkylphosphate, phosphate, cyano, nitro, alkoxy, alkoxycarbonyl, alkenyl, alkyn
• the present invention relates to compound of formula VII: wherein, each Zi and Z 2 is independently selected from optionally substituted hydroxy, phosphate, or heterocycloalkyl; and
• Ri 2 is hydrogen or O wherein R 21 is selected from group comprising optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl; wherein one or more substitution is selected from alkyl, amino, or cycloalkyl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound selected from group consisting of: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula VIII: wherein R 13 are selected from group comprising H; optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; and R 14 are selected from group comprising optionally substituted alkyl, aryl, heteroaryl, heterocycloalkyl, cycloalkyl; or R 13 and R 14 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of optionally substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, phosphonyl, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl,
• the present invention relates to compound of formula VIII: wherein R 13 and R 14 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and may optionally be substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, phosphonyl, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl,
• one or more substitution on radical R 21 is selected from group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, phosphate, alkylphosphate.
• the present invention relates to compound of formula wherein R 13 and R 14 are taken together along with the nitrogen to which they are attached to form a three to seven membered saturated, partially unsaturated or unsaturated heterocyclic ring and substituted at a substitutable position with one or more R 21 radicals, wherein the one or more R 21 radicals are independently selected at each occurrence from the group consisting of substituted alkyl, alkylcarbonyl, formyl, halo, haloalkyl, alkylphosphate, phosphate, phosphonyl, oxo, cyano, nitro, amino, alkoxy, alkoxycarbonyl, carboxyalkyl, hydroxyalkyl, alkenyl, alkynyl, alkylthio, cycloalkyl, aryl, heteroaryl, aralkyl, heterocycloalkyl, alkylthioalkyl, arylcarbonyl, aralkylcarbonyl, alkoxyalkyl
• one or more substitution on radical R 21 is selected from group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, amino, alkylamino, acyl, acyloxy, acylamino, aminocarbonyl, alkoxycarbonyl, alkoxyalkyloxy, alkoxycarbonyloxy, carbamate, sulfinyl, sulfonyl, alkoxy, sulfanyl, halogen, carboxy, trihalomethyl, cyano, hydroxy, mercapto, nitro, phosphate, alkylphosphate.
• the present invention relates to compound of formula VIII: wherein R 13 is selected from hydrogen, alkyl; and
• Ri 4 is selected from group comprising optionally substituted alkyl, heterocycloalkyl, or aryl; wherein one or more substitution is selected from alkyl, alkoxy, halo, heteroaryl, heterocycloalkyl, cycloalkyl, amino, or hydroxy; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound selected from group consisting of: pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to prodrugs of Fulvestrant of formula IX: wherein S is selected from O, C, or N; and
• T is selected from group comprising optionally substituted aryl, heteroaryl, heterocycloalkyl,
• the present invention relates to compound selected from group consisting of:
• the present invention relates to prodrugs of Fulvestrant of formula X: wherein, Q is selected from C or N; and when Q is C, Pi is selected independently from optionally substituted alkyl, optionally substituted ; wherein substitution on is alkyl; and P2 and P3 is selected independently from hydrogen or alkyl; and when Q is N, P2 is selected independently from optionally substituted alkyl, optionally substituted ⁇ wherein substitution on is alkyl; Pi is hydrogen and P3 is optionally substituted alkyl; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound selected from the group consisting of: and pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula XI: wherein R15 and Ri 6 together forms a cyclic structure; wherein the said cyclic structure is selected from optionally substituted cycloalkyl, or heterocycloalkyl; wherein one or more substitution is selected from alkyl, alkoxy, halo, amino, or hydroxy; m and n can be independently 1 to 3; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof.
• the present invention relates to compound of formula XI where m and n both are 1 or 2.
• the present invention relates to compound selected from the group consisting of: and pharmaceutically acceptable salts, solvates thereof.
• the present invention relates to compound selected from group consisting of:
• the present invention relates to meglumine salt of compound
• the present invention relates to dimeglumine salt of compound
• the present invention relates to compound
• the compounds of the present invention further can be delivered in a form of pharmaceutical composition
• a form of pharmaceutical composition comprising compound of invention and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients.
• the present invention relates to pharmaceutical composition
• pharmaceutical composition comprising Fulvestrant prodrug and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts or solvates thereof, and pharmaceutically acceptable excipients.
• the Fulvestrant prodrug for the said pharmaceutical composition is selected from the compound of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X and formula XI; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof.
• compositions of the present disclosure can be in any form known to those of skill in the art.
• the pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally or via an implanted reservoir, preferably oral administration or administration by injection.
• the pharmaceutical composition comprising desired product is formulated for oral delivery.
• the pharmaceutical composition comprising desired product is selected from a group consisting of a concentrate, dried powder, liquid, capsule, pellet, and pill.
• the pharmaceutical composition comprising desired product is for parenteral.
• the pharmaceutical composition comprising desired product is selected from a group consisting of a intravenous injection, intramuscular injection, subcutaneous injection, powder for solution for injection, powder for suspension for injection, liposome, oily injection, sustained release particles.
• compositions disclosed herein may also further comprise carriers, binders, diluents, and excipients.
• the disclosure provides for a pharmaceutical composition in the form of Fulvestrant prodrug for treatment of diseases and/or symptoms that are meant to be treated by the original drug molecule.
• the composition may comprise Fulvestrant prodrug in an amount that is as therapeutically effective as or more therapeutically effective than the original drug.
• the invention provides use of compounds of the present invention in the preparation of a pharmaceutical formulation as describe hereinabove, for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.
• the invention provides compounds for the treatment of a benign or malignant disease of the breast or reproductive tract, preferably treating breast cancer.
• the invention provides Fulvestrant prodmgs useful in the treatment of oestrogen-dependent indications such as breast cancer and gynaecological conditions, such as endometriosis.
• the Fulvestrant prodmgs for the said treatment of a benign or malignant disease of the breast or reproductive tract is selected from the compound of formula I, formula II, formula III, formula IV, formula V, formula V-A, formula VI, formula VII, formula VIII, formula IX, formula X and formula XI.
• the invention provides a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, comprising administration of a compound selected from formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof.
• the invention provides a method of treating a benign or malignant diseases of the breast or reproductive tract, preferably treating breast cancer, comprising administration of a compound selected from formula I, formula II, formula III, formula IV, formula V, formula V-A, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI; and enantiomers, diastereomers, racemates, pharmaceutically acceptable salts and solvates thereof.
• the present disclosure relates to new Fulvestrant prodrug and any stereochemically isomeric form, hydrate, solvate or pharmaceutically acceptable salt thereof; either alone or in combination with at least one additional therapeutic agent, in the treatment of diseases and/or symptoms meant to be treated by the original drugs.
• the combination with an additional therapeutic agent may take the form of combining the new Fulvestrant prodrug compounds with any known therapeutic agent.
• Example-01 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6FI- cyclopenta[a]phenanthren-3-yl (4-(piperidin-l-yl)phenyl)carbamate
• Example-02 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,ll,12,13,14,15,16,l , 7-decahydro-6H- cyclopenta[a]phenanthren-3-yl-4-(phosphonooxy)piperidine-l-carboxylate
• Step-1 Preparation of tert-butyl 4-((bis(benzyloxy)phosphoryl)oxy)piperidine-l-carboxylate
• Step-2 Preparation of Dibenzyl piperidin-4-yl phosphate (Trifluoro acetate salt)
• Step-3 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-4-((bis(benzyloxy)phosphoryl)oxy)piperidine-l-carboxylate
• Step-4 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-4-(phosphonooxy)piperidine-l-carboxylate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-3-((bis(benzyloxy)phosphoryl)oxy)-13-methyl-7- (9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren- 17-yl 3-(dimethylamino)propanoate
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfmyl)nonyl)-3-(phosphonooxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren- 17-yl 3-(dimethylamino)propanoate
• Example-04 Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-3-(phosphonooxy)-7,8,9,l 1,12,13,14,15,16,17-decahydro- 6H-cyclopenta[a]phenanthren-17-yl [l,4'-bipiperidine]-l'-carboxylate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-3-((bis(benzyloxy)phosphoryl)oxy)-13-methyl-7- (9-((4,4,5,5,5-pentafluoropentyl)sulfmyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren- 17-yl [1
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-3-(phosphonooxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren- 17-yl [1 ,4'-bipiperidine] - 1 '-carboxylate
• a solution of (7R,8R,9S,13S,14S,17S)-3-((bis(benzyloxy)phosphoryl)oxy)-13-methyl-7-(9- cyclopenta[a]phenanthren-17-yl [l,4'-bipiperidine]-1'-carboxylate crude 0.250 mg) in trifluoroacetic acid (6 mL) was stirred at 70°C for 2h.
• reaction mass was cooled to room temperature and concentrated under reduced pressure to obtain the crude material (200 mg, 19% pure by LCMS).
• the crude was purified by prep HPLC and the product fractions were lyophilized to give 0.02 g of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9- ((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-3-(phosphonooxy)-7,8,9,11,12,13,14,15,16,17- decahydro-6H-cyclopenta[a]phenanthren-17-yl [l,4'-bipiperidine]-l'-carboxylate as a white colour solid.
• Example-05 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-methyl((2S,3R,4R,5R)-2,3,4,5,6- pentahydroxyhexyl)carbamate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl (4-nitrophenyl) carbonate
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-methyl((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)carbamate
• Example-06 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,l 1,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-(l,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (4-nitrophenyl) carbonate
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfmyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-(l,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (4-nitrophenyl) carbonate
• Example-08 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,l 1,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl(1'-methyl-[l,4'-bipiperidin]-4-yl)carbamate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (4-nitrophenyl) carbonate
• Fulvestrant 2.0 g
• acetonitrile 20 mL
• caesium carbonate 3.24 g
• 4-nitrophenyl chloroformate (0.99 g
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl( 1'-methyl-[1,4 ' -bipiperidin]-4-yl)carbamate
• reaction mixture was monitored by TLC (mobile phase: 70% ethyl acetate in Hexane). After completion of the reaction, the mixture was diluted with water and extracted with ethyl acetate (3 x 120 mL). The combined organic layer was dried over anhydrous sodium sulphate and evaporated under reduced pressure to obtained crude material.
• Example-09 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5, 5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta [a]phenanthren-3-yl 4-(pyrrolidin-l-yl)piperidine-l-carboxylate
• Example-10 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9- ((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl-9-methyl-3,9-diazaspiro[5.5]undecane-3-carboxylate
• Example-11 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9- ((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 6-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-67/-cyclopenta[a] phenanthren-3-yl(4-nitrophenyl) carbonate
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 6-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylate
• Example 12 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (2-(dimethylamino)ethyl)(methyl)carbamate
• Example 13 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 4-(pyridin-4-yl)piperidine-l-carboxylate
• Step-1 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl(4-nitrophenyl) carbonate
• Step-2 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5-penta fluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl-4-(pyridin-4-yl)piperidine-l-carboxylate
• Example-14 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a] phenanthren-3-yl 4-(dimethylamino)piperidine-l-carboxylate
• Example-15 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 4-(l,4-oxazepan-4-yl)piperidine-l-carboxylate:
• Example-16 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 3-oxa-9-azaspiro[5.5]undecane-9-carboxylate:
• Example-17 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (4-(l-methylpiperidin-4-yl)phenyl)carbamate
• Example-18 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (4-morpholinophenyl)carbamate
• Example-19 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl (2-(dimethylamino)ethyl)carbamate
• Example-20 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 4-morpholinopiperidine-l-carboxylate
• Example-21 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 4-(4-methylpiperazin-l-yl)piperidine-l-carboxylate
• Example-22 Preparation of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-17-(phosphonooxy)-7,8,9,ll,12,13,14,15,16,l , 7- decahydro-6H-cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]-1'-carboxylate
• Step-1 To a solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]-l'-carboxylate (0.500 g) in THF (5 mL) was added NaHMDS (1.25 mL) at 0°C. The resulting reaction mixture was stirred at the same temperature for 30 min.
• reaction mixture was stirred at rt for 16h. After completion of reaction by LCMS, the reaction mixture was diluted with water and extracted with EtOAc.
• Step-2 To a solution of (7R,8R,9S,13S,14S,17S)-17-((bis(benzyloxy)phosphoryl)oxy)-13- methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro- 6H-cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]-1'-carboxylate (step-1 product 0.550 g) in TFA (6 mL) was stirred at 80°C for 3h.
• reaction mixture was cooled to rt and concentrated under reduced pressure to obtained the crude material (450 mg, 21% pure by LCMS) which was purified by prep HPLC and obtained 23 mg of (7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-17- (phosphonooxy)-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl [1,4'- bipiperidine]- l'-carboxylate LCMS purity: 97%
• Example-23 Preparation of (7R,8R,9S,13S,14S,17S)-17-((D-valyl)oxy)-13-methyl-7-(9- ((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]-1'-carboxylate
• Step-1 To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfmyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]- l'-carboxylate (0.5 g) in DMF (10 mL) were added DCC (0.386 g) and DMAP (0.045 g) at room temperature.
• Step-2 To a solution of (7R,8R,9S,13S,14S,17S)-17-(((tert-butoxycarbonyl)-D-valyl)oxy)-13- methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro- 6H-cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]- l'-carboxylate (Step-1 product 0.8 g) in DCM (50 mL) was added TFA (10 mL) at 0°C.
• reaction mixture was stirred at room temperature for 16h. After completion of the reaction (monitored by LCMS), the reaction mixture was concentrated under reduced pressure at 25-28°C to obtain 0.7 g of (7R,8R,9S,13S,14S,17S)- 17-((D-valyl)oxy)-13-methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)- 7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl [l,4'-bipiperidine]- 11- carboxylate as a brown sticky oil.
• Example-25 Preparation of 2-hydroxy-4-(((7R,8R,9S,13S,14S,17S)-l 7-hydroxy- 13-methyl- 7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl) nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl)oxy)-4-oxobutanoic add
• Step-1 To a stirred solution of Fulvestrant (0.7g) and 2-(2,2-dimethyl-5-oxo-l,3-dioxolan-4- yl) acetic acid (0.201g) in DCM were added DIPEA (1 mL), EDC.HC1 (0.661 g) and HOBt (0.265 g) followed by DMAP (0.028 g) and the resulting reaction mixture was vigorously stirred at room temperature for 16h.
• the reaction mixture was diluted with water and extracted with ethyl acetate, dried the organic layer over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the (7R,8R,9S,13S,14S,17S)-17-hydroxy-13- methyl-7-(9-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro- 6H-cyclopenta[a]phenanthren-3-yl 2-(2,2-dimethyl-5-oxo-l,3-dioxolan-4-yl)acetate (0.7 g, LCMS purity 49%) as viscous oil, which was used without purification for the next step.
• Step-2 To a stirred solution of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl) sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl 2-(2,2-dimethyl-5-oxo -1, 3 -dioxolan-4-yl) acetate (obtained from step-1, 0.7 g) in THF (7 mL) was added 2N HC1 (7 mL) at 0°C and the reaction mixture was then stirred at 70°C for 6h.
• Example-26 Preparation of tetraethyl ((7R,8R,9S,13S,14S,17S)-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthrene-3,17-diyl) bis(phosphate)
• Example-27 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,11,12,13,14,15,16,17 -decahydro-6H- cyclopenta[a]phenanthren-3-yl dihydrogen phosphate, di(2S,3R,4R,5R)-2,3,4,5,6- pentahydroxy-N-methylhexan-l-aminium salt (dimeglumine salt)
• reaction mixture was lyophilized to afford (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropenty 1) sulfiny l)nonyl) -7 , 8,9,11,12,13, 14,15,16,17 -decahy dro- 6H- cyclopenta[a]phenanthren-3-yl dihydrogen phosphate, di(2S, 3R,4R,5R)-2, 3,4,5, 6-pentahydroxy- N-methylhexan-l-aminium salt as a white solid (yield: 0.095 g, purity 96.12% by LCMS).
• Example-28 Preparation of (7R,8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-7-(9-((4,4,5,5,5- pentafluoropentyl)sulfinyl)nonyl)-7,8,9,ll,12, 13,14,15,16,17-decahydro-6H- cyclopenta[a]phenanthren-3-yl dihydrogen phosphate di(2-amino-2-(hydroxy methyl)propane-l,3-diol)
• reaction mixture was lyophilized to afford cyclopenta[a]phenanthren-3-yl dihydrogen phosphate di(2-amino-2-(hydroxy methyl)propane- 1,3-diol) as a white solid (yield: 0.077 g, purity 96.67% by LCMS).

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Steroid Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (7)

Applications Claiming Priority (4)

Publications (2)

Family

ID=75980095

Family Applications (1)

Country Status (7)

Cited By (4)

Family Cites Families (8)

• 2020
  • 2020-11-24 EP EP20891095.0A patent/EP4061376A4/en active Pending
  • 2020-11-24 WO PCT/IB2020/061065 patent/WO2021100029A2/en not_active Ceased
  • 2020-11-24 US US17/779,015 patent/US20230137764A1/en not_active Abandoned
  • 2020-11-24 CA CA3162182A patent/CA3162182A1/en active Pending
  • 2020-11-24 CN CN202080093658.5A patent/CN115151260A/zh active Pending
  • 2020-11-24 AU AU2020386864A patent/AU2020386864A1/en active Pending
  • 2020-11-24 JP JP2022529452A patent/JP2023503898A/ja active Pending
• 2025
  • 2025-11-21 JP JP2025202023A patent/JP2026032104A/ja active Pending

Also Published As

Similar Documents

Legal Events